The DCTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the DCTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The DCTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View DCTH Detailed Price Forecast - CNN Money||View DCTH Detailed Summary - Google Finance|
|View DCTH Detailed Summary - Yahoo! Finance||View DCTH Stock Research & Analysis - Zacks.com|
|View DCTH Trends & Analysis - Trade-Ideas||View DCTH Major Holders - Barrons|
|View DCTH Call Transcripts - NASDAQ||View DCTH Breaking News & Analysis - Seeking Alpha|
|View DCTH Annual Report - CompanySpotlight.com||View DCTH OTC Short Report - OTCShortReport.com|
|View DCTH Fundamentals - TradeKing||View DCTH SEC Filings - Bar Chart|
|View Historical Prices for DCTH - The WSJ||View Performance/Total Return for DCTH - Morningstar|
|View the Analyst Estimates for DCTH - MarketWatch||View the Earnings History for DCTH - CNBC|
|View the DCTH Earnings - StockMarketWatch||View DCTH Buy or Sell Recommendations - MacroAxis|
|View the DCTH Bullish Patterns - American Bulls||View DCTH Short Pain Metrics - ShortPainBot.com|
|View DCTH Stock Mentions - StockTwits||View DCTH Stock Mentions - PennyStockTweets|
|View DCTH Stock Mentions - Twitter||View DCTH Investment Forum News - Investor Hub|
|View DCTH Stock Mentions - Yahoo! Message Board||View DCTH Stock Mentions - Seeking Alpha|
|View Insider Transactions for DCTH - SECform4.com||View Insider Transactions for DCTH - Insider Cow|
|View DCTH Major Holdings Summary - CNBC||View Insider Disclosure for DCTH - OTC Markets|
|View Insider Transactions for DCTH - Yahoo! Finance||View Institutional Holdings for DCTH - NASDAQ|
|View DCTH Stock Insight & Charts - FinViz.com||View DCTH Investment Charts - StockCharts.com|
|View DCTH Stock Overview & Charts - BarChart||View DCTH User Generated Charts - Trading View|
Delcath Announces Third Quarter Fiscal 2018 Financial Results
Posted on Tuesday November 13, 2018
NEW YORK, Nov. 13, 2018 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces.
Delcath Announces Enrollment of First Patient in ALIGN Trial
Posted on Thursday October 18, 2018
Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that patient treatments have begun in the Company’s second global US registration trial investigating Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) in the treatment of patients with intrahepatic cholangiocarcinoma (ICC). The University of Tennessee Health Science Center (UTHSC) in collaboration with Methodist University Hospital (MUH) and West Cancer Center (WCC) in Memphis, Tennessee have enrolled the trial’s first patient and treatments have begun by a team led by Dr. Evan S. Glazer.
Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
Posted on Monday October 15, 2018
Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces the addition of six major cancers in the United States that have adopted the amended trial protocol for the company’s registration trial in ocular melanoma liver metastases.
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology
Posted on Thursday October 04, 2018
Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results of a multicenter analysis of outcomes in patients with intrahepatic cholangiocarcinoma (ICC) treated with CHEMOSAT has been published in the journal European Radiology. The study is the first analysis on the use of Delcath’s PHP® Therapy for the treatment of ICC. The retrospective analysis—Percutaneous Hepatic Perfusion (Chemosaturation) with Melphalan in Patients with Intrahepatic Cholangiocarcinoma: European Multicentre Study on Safety, Short Term Effects and Survival—was conducted by investigators in Germany, Italy, Netherlands, Spain and France with Dr. Steffen Marquardt of Hannover Medical School serving as lead author.